跳至主要内容
临床试验/NCT05982509
NCT05982509已完成不适用

Clinical Trial to Assess the Efficacy and Safety of Neopop-S Containing EASYDEW

Eun-ji Kim1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2022年11月11日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
20
试验地点
1
主要终点
Transepidermal water loss Transcutaneous water loss (TEWL) measured

研究概览

简要总结

The purpose of this clinical study is to evaluate the effect on skin regeneration after applying EasyDew MD Regen Cream containing Neopep-S, a regeneration factor, to patients who have undergone picosure picosure laser skin treatment as needed.

详细描述

This clinical study is a researcher-led randomized control group comparative clinical study that is conducted prospectively for one month after applying medical devices for clinical research.

The subjects are those who have undergone a picosure laser procedure for therapeutic purposes on the skin tissue of the face or body, and a screening test is conducted after the subject (and/or legal representative) agrees in writing to participate in the clinical study.

The screening test results are evaluated, and subjects who meet the selection criteria and do not meet the exclusion criteria are registered in clinical research.

Participating subjects are randomly assigned to the control group and the study group using a random number table at a 5:5 ratio.

  • Control group: 10 people without treatment
  • Study Group: 10 People Applying EasyDu Regen MD Cream Clinical study subjects are randomly assigned to control and study groups. In the case of the study group, the Easy Dew Regen MD cream provided through prescription is applied twice a day (morning and evening) to the skin of the area where the picosure laser treatment has been performed and absorbed well. The control group is the non-chalant group. However, general moisturizers that were used at home rather than medical devices for one month after the procedure can be used, and they are applied twice a day (morning and evening) to the skin of the area where the laser treatment has been performed and absorbed well.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
19 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Those aged 19 to 65 who have undergone picosure laser treatment on facial and body skin tissues
  • Decided to participate in this clinical study and signed a written informed consent the subject

排除标准

  • Subjects with uncontrolled diabetes
  • Subjects with uncontrolled hypertension and cardiovascular disease
  • Subjects with hemorrhagic diseases such as hemophilia
  • Immunosuppressants, corticosteroids, cytotoxic agents, and anticoagulants can affect the results Subjects who are or are scheduled to receive medication for an extended period of time
  • Acute or chronic skin disease causes stage progression or active bacteria in the application area Who has a virus infection
  • When the researcher's judgment determines that participation in the study is inappropriate (e.g. keloid constitution)

结局指标

主要结局

Transepidermal water loss Transcutaneous water loss (TEWL) measured

时间窗: Before, immediately after treatment, and one month after application

Before, immediately after treatment, and one month after application of the medical device Transcutaneous water loss (TEWL) measured

次要结局

未报告次要终点

研究者

发起方
Eun-ji Kim
申办方类型
Industry
责任方
Sponsor Investigator
主要研究者

Eun-ji Kim

Clinical Trial Manager

CGBio Inc.

研究点 (1)

Loading locations...

相似试验